KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will be presenting at the 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference on October 6, 2011 at 3:45 p.m. at the New York Academy of Medicine in New York City.
Craig Dees, Ph.D., Chairman and Chief Executive Officer of Provectus will discuss PV-10’s immunologic potential in treating melanoma and other cancer indications including liver, pancreatic and colorectal cancer. Dr. Dees will also discuss work that is being done on PV-10’s mechanism of action, as well as other research that is being conducted.
PV-10 is Provectus’s novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, thereby reducing potential for systemic side effects.
Dr. Dees noted, “PV-10 is remarkable as a small molecule drug since it may induce systemic effects similar to those observed with immunotherapy or a vaccine. The simplicity of PV-10 and breadth of response compares favorably to these conventional approaches.”
Further information the conference can be found at the following link: www.regonline.com/mdbpartners.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
Forward Looking Statement- Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Provectus Pharmaceuticals, Inc.’s filings with the United States Securities and Exchange Commission, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.